Röllig, C., Schliemann, C., Ruhnke, L., Fransecky, L., Heydrich, B., Hanoun, M., . . . Bornhäuser, M. (2024). Gemtuzumab ozogamicin plus midostaurin in combination with standard ‘7 + 3’ induction therapy in newly diagnosed AML: Results from the SAL-MODULE phase I study. British journal of haematology, 204(6), . https://doi.org/10.1111/bjh.19436
Chicago-Zitierstil (17. Ausg.)Röllig, Christoph, et al. "Gemtuzumab Ozogamicin Plus Midostaurin in Combination with Standard ‘7 + 3’ Induction Therapy in Newly Diagnosed AML: Results from the SAL-MODULE Phase I Study." British Journal of Haematology 204, no. 6 (2024). https://doi.org/10.1111/bjh.19436.
MLA-Zitierstil (9. Ausg.)Röllig, Christoph, et al. "Gemtuzumab Ozogamicin Plus Midostaurin in Combination with Standard ‘7 + 3’ Induction Therapy in Newly Diagnosed AML: Results from the SAL-MODULE Phase I Study." British Journal of Haematology, vol. 204, no. 6, 2024, https://doi.org/10.1111/bjh.19436.